24/7 Market News Snapshot 15 July, 2025 – Kairos Pharma, Ltd. (NYSE:KAPA)

July 15, 2025

DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (NYSE:KAPA) are discussed in this article.
Kairos Pharma, Ltd. has emerged as a significant player in the biopharmaceutical sector, recently attracting considerable attention in the financial markets. The company’s stock price surged by an impressive 23.05% in pre-market trading, reaching $0.843, up from the previous close of $0.685. This sharp price increase, accompanied by a trading volume of 9.58 million shares, reflects strong investor confidence and growing interest in the company’s future potential.

This momentum coincides with the announcement of promising results from Kairos Pharma’s ongoing Phase 2 clinical trial of ENV-105 (carotuximab), aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The interim analysis revealed that ENV-105 demonstrated a favorable safety profile in combination with standard hormone therapy, apalutamide, among the first ten patients enrolled. Notably, the trial reported no significant dose-limiting toxicities or unexpected adverse events, indicative of manageable treatment-related side effects.

Dr. John Yu, CEO of Kairos Pharma, expressed his optimism regarding the trial’s outcomes, emphasizing the potential of ENV-105 to meet an urgent unmet need in mCRPC treatment. With prostate cancer impacting over one million men in the United States alone, the urgency for effective therapeutic alternatives is paramount, especially as current hormone therapies often face issues of resistance.

The Phase 2 trial, targeting an enrollment of 100 patients across prominent cancer centers, aims to assess safety, tolerability, and early efficacy signals of ENV-105. With interim efficacy data expected by September 2025, Kairos Pharma is actively engaging with regulatory agencies to discuss the potential design of a pivotal Phase 3 study. This proactive approach underscores the company’s commitment to advancing innovative treatments for patients grappling with this challenging disease.

Related news for (KAPA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.